| Literature DB >> 27314324 |
Shahnaz Bakand1,2, Amanda Hayes3.
Abstract
Novel engineered nanoparticles (NPs), nanomaterial (NM) products and composites, are continually emerging worldwide. Many potential benefits are expected from their commercial applications; however, these benefits should always be balanced against risks. Potential toxic effects of NM exposure have been highlighted, but, as there is a lack of understanding about potential interactions of nanomaterials (NMs) with biological systems, these side effects are often ignored. NPs are able to translocate to the bloodstream, cross body membrane barriers effectively, and affect organs and tissues at cellular and molecular levels. NPs may pass the blood-brain barrier (BBB) and gain access to the brain. The interactions of NPs with biological milieu and resulted toxic effects are significantly associated with their small size distribution, large surface area to mass ratio (SA/MR), and surface characteristics. NMs are able to cross tissue and cell membranes, enter into cellular compartments, and cause cellular injury as well as toxicity. The extremely large SA/MR of NPs is also available to undergo reactions. An increased surface area of the identical chemical will increase surface reactivity, adsorption properties, and potential toxicity. This review explores biological pathways of NPs, their toxic potential, and underlying mechanisms responsible for such toxic effects. The necessity of toxicological risk assessment to human health should be emphasised as an integral part of NM design and manufacture.Entities:
Keywords: inhalation; nanomaterials; nanoparticles; physicochemical properties; risk assessment; toxicity mechanism
Mesh:
Year: 2016 PMID: 27314324 PMCID: PMC4926462 DOI: 10.3390/ijms17060929
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Nano-objects; related terms and geometrical characteristics.
| Nano-Objects | Nanoparticle | Nanofibre or Nanotube | Nanoplate |
|---|---|---|---|
| Geometrical Characteristics | Isometric 3 ext. dimensions in nanoscale | One-dimensional (1D) 2 ext. dimensions in nanoscale | Two-dimensional (2D) 1 ext. dimension in nanoscale |
| Example | Bucky ball | Carbon nanotubes (CNTs) | Graphene |
Figure 1Biokinetics of nanoparticles (modified from [3]). Solid arrows: Confirmed routes; Dashed arrows: Potential routes; CNS: Central nervous system; PNS: Peripheral nervous system; GI: Gastrointestinal; IV: Intravenous.
Nanomaterial properties and possible biological effects.
| Nanomaterial Properties | Potential Biological Effects |
|---|---|
| Size/size distribution (aerodynamic, hydrodynamic) | Crossing tissue and cell membranes |
| Cellular injury | |
| Phagocytosis impairment, breakdown in defense mechanisms | |
| Migration to other organs | |
| Transportation of other environmental pollutants | |
| Surface properties Surface area/mass ratio | Increased reactivity |
| Increased toxicity | |
| Chemical composition Surface characteristics | ROS generation |
| Oxidative stress | |
| Inflammation | |
| Cytokine production | |
| Glutathione depletion | |
| Mitochondrial exhaustion | |
| Cellular injury | |
| Protein and DNA damage | |
| Insolubility or low water solubility | Bioaccumulation inside living systems such as human cells, tissues and lungs |
| Potential long-term effects | |
| Agglomeration/aggregation | Interruption of cellular processes |
| Cellular injury |
Risk management framework relevant to nanomaterials.
| Risk Management | Details of Each Step Relevant to Nanomaterials |
|---|---|
| Identify hazard | Describe nanomaterial & applications |
| Determine nanomaterial profiles | |
| Physicochemical profiles | |
| Hazard profiles | |
| Exposure profiles | |
| Evaluate risk | Based on the combination of: Identified hazards, exposure, potential risks |
| Exposure patterns: including likelihood and severity | |
| Control risk | Level 1: Eliminate the hazard |
| Eliminating the nanomaterial | |
| Level 2: Substitute, Isolate and engineering controls | |
| Substitute to a safer material, product or process | |
| Apply process containment | |
| Use local exhausted ventilation systems equipped with efficient filters (e.g., HEPA) | |
| Level 3: Reduce exposure by | |
| Administrative controls (e.g., develop Safety data sheets and safe work procedures) | |
| Personal protective equipment (e.g., appropriate gloves, eye and respiratory protection) | |
| Decide, document & act | Decide: Whether or in what capacity to continue development and production of the nanomaterial |
| Sharing information with the stakeholders | |
| Further information to be collected | |
| Review & adapt | Update the risk assessment process through: Regular reviews |
| Reviews triggered by specific events |